الفهرس Only 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Hepatic fibrogenesis is fundamental clinically serious problem in various types of chronic liver diseases.
Hepatic stellate cells, (HSCs) are believed to play a pivotal role in fibrogenesis in the liver.
HSCs have been shown to express peroxisome proliferator-activated receptor (PPAR γ),a general type isoform of PPAR.
Pioglitazone (PGZ), one member of thiazolidinedione (TZDs), is used to improve insulin resistance in type II diabetes as the ligand of the PPARγ.
PPARY ligand has been reported improving hepatic steatosis, alanine aminotransferase elevation,and insulin sensitivity in patients with non-alcoholic steatohepatitis (NASH).PPARY ligands have also been reported to inhibit cell proliferation and collagen expression in primary hepatic stellate cells both in vitro and in vivo These results suggest a potential value for PPARγ agonists in treating hepatic fibrosis The aim of this work is to investigate the therapeutic potential of pioglitazone on hepatic fibrosis, induced by CCL4 in rats. PGZ will be introduced at various time points after induction of hepatic fibrosis.
The therapeutic antifibrotic effect of PGZ treated animals versus untreated fibrotic controls.